Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Satsuki Ando is active.

Publication


Featured researches published by Satsuki Ando.


Hepatology Research | 2014

Therapeutic strategy for patients with bleeding rectal varices complicating liver cirrhosis

Kiyoko Yoshino; Yukinori Imai; Manabu Nakazawa; Taku Chikayama; Satsuki Ando; Kayoko Sugawara; Kazuhiro Hamaoka; Mie Inao; Masashi Oka; Satoshi Mochida

Although rupture of rectal varices is rarely encountered, it may provoke massive and fatal hemorrhage in patients with liver cirrhosis. We examined the clinical features of patients showing bleeding from rectal varices to establish a suitable therapeutic strategy for the lesions.


Journal of Gastroenterology and Hepatology | 2016

Long‐Term Outcome of 154 Patients Receiving Balloon‐Occluded Retrograde Transvenous Obliteration for Gastric Fundal Varices

Yukinori Imai; Manabu Nakazawa; Satsuki Ando; Kayoko Sugawara; Satoshi Mochida

This study aims to clarify the long‐term outcome of therapeutic strategies including balloon‐occluded retrograde transvenous obliteration (B‐RTO) for patients with gastric fundal varices.


Journal of Gastroenterology and Hepatology | 2014

Balloon-occluded retrograde transvenous obliteration using a microballoon catheter for intractable gastric fundal varices.

Yukinori Imai; Manabu Nakazawa; Satsuki Ando; Kayoko Sugawara; Kazuhiro Hamaoka; Masashi Oka; Satoshi Mochida

Balloon‐occluded retrograde transvenous obliteration (B‐RTO) is recognized as the standard therapy for patients with gastric fundal varices in Japan; however, the procedure is difficult when drainage veins other than the gastrorenal shunt developed. The efficacy and safety of B‐RTO using a microballoon catheter for such patients were evaluated.


Clinical Journal of Gastroenterology | 2011

A case of liver cirrhosis due to hepatits C virus infection complicating giant anorectal varices treated with balloon-occluded retrograde transvenous obliteration.

Kazuhiro Watanabe; Yukinori Imai; Hiroaki Takaya; Manabu Nakazawa; Taku Chikayama; Satsuki Ando; Yoshie Mizuno; Kayoko Sugawara; Yuuka Nakamura; Eiko Saitoh; Kazuhiro Hamaoka; Daisuke Motoya; Kenji Fujimori; Mie Inao; Nobuaki Nakayama; Sumiko Nagoshi; Satoshi Mochida

A 73-year-old man with liver cirrhosis due to hepatitis C virus infection was admitted to our hospital because of massive bleeding from external varices. Colonoscopic examination revealed that giant anorectal varices had developed between the anus and rectal ampulla, and had ruptured at the perianal site. On three-dimensional computed tomography imaging, the feeding and drainage vessels of the varices were identified as the inferior mesenteric vein and right inferior hemorrhoidal vein, respectively. Endoscopic therapies were not employed for the bleeding varices, because the blood flow volume of the feeding vessel was extremely large. Balloon-occluded retrograde transvenous obliteration (B-RTO) was therefore carried out through the drainage vessels. The variceal blood flow disappeared after B-RTO therapy, and the varices decreased in size with thrombus formation verified by colonoscopy. Bleeding from the external varices also ceased. B-RTO therapy may be an effective approach for giant anorectal varices presenting as a complication in liver cirrhosis patients in whom the main drainage vessels can be determined.


Hepatology Research | 2014

Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin.

Takahiro Handa; Yukinori Imai; Kayoko Sugawara; Taku Chikayama; Manabu Nakazawa; Satsuki Ando; Kazuhiro Hamaoka; Mie Inao; Nobuaki Nakayama; Satoshi Mochida

The therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin was evaluated in comparison with that using epirubicin in patients with hepatocellular carcinoma (HCC).


Hepatology Research | 2018

Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy

Hayato Uemura; Yoshihito Uchida; Jun-ichi Kouyama; Kayoko Naiki; Shinpei Yamaba; Akira Fuchigami; Yoichi Saito; Keisuke Shiokawa; Yohei Fujii; Hiroshi Uchiya; Manabu Nakazawa; Satsuki Ando; Masamitsu Nakao; Daisuke Motoya; Kayoko Sugawara; Mie Inao; Yukinori Imai; Nobuaki Nakayama; Tomoaki Tomiya; Satoshi Mochida

To improve the therapeutic efficacy of sofosbuvir/ledipasvir (SOF/LDV) for the retreatment of patients after daclatasvir/asunaprevir (DCV/ASV), a customized therapy with or without lead‐in interferon (IFN)‐β injections was formulated according to the types of resistance‐associated substitutions (RAS) in the non‐structural protein (NS)5A region of genotype 1b hepatitis C virus (HCV).


Hepatology Research | 2018

A Case of Chronic Hepatitis Caused by Hepatitis C Virus Exhibiting a Discrepancy Between Serogroup and Genotype Because of Inter-Genotypic 2b/1b Recombination - A Pitfall in Antiviral Therapy with Direct-Acting Antivirals -

Hayato Kurata; Yoshihito Uchida; Jun-ichi Kouyama; Kayoko Naiki; Manabu Nakazawa; Satsuki Ando; Masamitsu Nakao; Daisuke Motoya; Kayoko Sugawara; Mie Inao; Yukinori Imai; Nobuaki Nakayama; Tomoaki Tomiya; Satoshi Mochida

A 40‐year‐old male patient with virologic relapse after daclatasvir plus asunaprevir therapy for a serogroup 1 hepatitis C virus (HCV) infection visited our hospital for retreatment. Virologic examinations revealed that a genotype 2b HCV strain carrying both NS3‐S122N / D168A and NA5A‐R30Q / L31M / Q54H / Y93H mutations had relapsed. The patient received sofosbuvir plus ribavirin therapy, but virologic relapse occurred once again. Sequencing of the HCV genome clarified an intergenotypic recombination of 2b and 1b with an estimated crossover point between nucleotides 3114 and 3115, corresponding to the N‐terminal end of the NS3 region (DDBJ/EMBL/GenBank databases accession no. LC273304). The NS5B‐S282T mutation was not detected in the HCV strain, and resistance‐association substitutions in the NS3 and NS5A regions were similar to those at baseline. Direct sequencing of the core and NS4A regions corresponding to the targeting sites of genotyping and serogrouping, respectively, is useful to determine the combination of direct‐acting antivirals when a discrepancy is observed between the serogroup and genotype of HCV strains.


Journal of Gastroenterology and Hepatology | 2017

Balloon-occluded retrograde transvenous obliteration as a procedure to improve liver function in patients with decompensated cirrhosis: Shunt occlusion to improve liver function

Manabu Nakazawa; Yukinori Imai; Hiroshi Uchiya; Satsuki Ando; Kayoko Sugawara; Nobuaki Nakayama; Tomoaki Tomiya; Satoshi Mochida

Portosystemic shunts aggravate liver function by decreasing portal blood flow. The usefulness of balloon‐occluded retrograde transvenous obliteration (B‐RTO), a standardized therapeutic procedure for gastric fundal varices (GFV), for the improvement of liver function was evaluated in cirrhotic patients with or without varices.


Journal of Gastroenterology | 2012

Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma

Yukinori Imai; Taku Chikayama; Manabu Nakazawa; Kazuhiro Watanabe; Satsuki Ando; Yoshie Mizuno; Kiyoko Yoshino; Kayoko Sugawara; Kazuhiro Hamaoka; Kenji Fujimori; Mie Inao; Nobuaki Nakayama; Masashi Oka; Sumiko Nagoshi; Satoshi Mochida


Journal of Gastroenterology | 2016

Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing

Yoshihito Uchida; Jun-ichi Kouyama; Kayoko Naiki; Kayoko Sugawara; Satsuki Ando; Masamitsu Nakao; Daisuke Motoya; Mie Inao; Yukinori Imai; Nobuaki Nakayama; Satoshi Mochida

Collaboration


Dive into the Satsuki Ando's collaboration.

Top Co-Authors

Avatar

Satoshi Mochida

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Yukinori Imai

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Kayoko Sugawara

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Manabu Nakazawa

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Mie Inao

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Nobuaki Nakayama

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Kazuhiro Hamaoka

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Taku Chikayama

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Kenji Fujimori

Saitama Medical University

View shared research outputs
Top Co-Authors

Avatar

Daisuke Motoya

Saitama Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge